← stocks-llm Find companies like UPB →

UPSTREAM BIO INC (UPB)

Health Care · Clinical-stage monoclonal antibody / TSLP-targeting biologics · NASDAQ

Upstream Bio is developing verekitug, a highly potent TSLP receptor antagonist monoclonal antibody targeting severe respiratory inflammatory diseases with extended quarterly dosing intervals.

View SEC filings Website Yahoo Finance Find companies like UPB → Ask about UPB →

What UPSTREAM BIO INC does

Upstream Bio is a clinical-stage biotechnology company developing verekitug, a monoclonal antibody that targets the TSLP receptor to treat inflammatory diseases, with an initial focus on severe respiratory disorders including severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company has advanced verekitug into Phase 2 trials across these indications, with positive top-line results reported in CRSwNP and severe asthma, and plans to initiate Phase 3 trials in both indications in the first quarter of 2027. Verekitug is designed to be approximately 300-fold more potent than the approved TSLP ligand antagonist tezepelumab, enabling extended dosing intervals of up to 24 weeks compared to tezepelumab's four-week dosing schedule.

Themes: ["TSLP / inflammatory disease","Severe asthma treatment","Chronic rhinosinusitis with nasal polyps (CRSwNP)","COPD treatment","Monoclonal antibodies / biologics","Clinical-stage biotech"]

Fundamentals

Ask why UPB looks like this →

Key risks (from latest filing)

["Verekitug is still in Phase 2 development; clinical advancement to Phase 3 is uncertain, and clinical trial failures could halt development and deplete cash reserves.","Established competitor tezepelumab (Tezspire, marketed by Amgen/AstraZeneca) already approved and capturing significant market share in severe asthma; failure to differentiate verekitug on efficacy or safety could limit market adoption.","Company is pre-revenue from product sales (only collaboration revenue), with negative net margin of -4718.96% and significant cash burn; funding requirements for Phase 3 trials and commercialization are substantial and success depends on raising capital."]

See UPB's biggest risks from its latest 10-Q →

Competitors & peers

Not quite? Describe exactly what you want →

Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.

Last updated 2026-07-09.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.